Ciphergen has appointed Wendell Wierenga, CEO of Syrrx, to its board of directors. Wierenga joined Syrrx as CEO in September 2000, and in previous positions has served as a senior vice president for worldwide pharmaceutical sciences, technology, and development at Pfizer, and as senior vice president of the Parke-Davis Pharmaceutical Research division of Warner-Lambert.
Daniel Gold has joined Human Genome Sciences as senior vice president for process development, the company said last week. In his new position, Gold will be responsible for overseeing the development of manufacturing processes for the production of therapeutic proteins and antibody drugs. In his most recent position, Gold served as vice president for process development and chief scientific officer of Diosynth-RTP, a contract biopharmaceutical process development and manufacturing division of Akzo Nobel. He will report to Craig Rosen, HGS' executive vice president for research and development.
Woburn, Mass.-based U.S. Genomics has appointed Craig Venter to its board of directors and named him as a scientific advisor, the company said last week. This is Venter's first such job in a private-sector setting since leaving Celera Genomics in January.
Matthew Trunnell has joined GeneData of South San Francisco as head of technology for the company’s West Coast office. Dennis Bittner has also joined the company as director of marketing.